This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Discussing the recent phase 2 results from infigratinib in children with achondroplasia and how it may compare to Biomarin's Voxzogo (vosoritide)

Ticker(s): BBIO, BMRN

Who's the expert?

Institution: OHSU

  • Professor and Chair (emeritus) of Pediatrics, Oregon Health & Science University
  • Has treated patients with achondroplasia for 40 years, currently involved in treatment decisions for 6 patients. 
  • Internationally renowned authority on the endocrine basis of growth and development and has been at the forefront of understanding the biology of growth hormone (GH) and growth factors for over 30 years.

Interview Questions

How many patients do you manage with achondroplasia?

Added By: wilson_admin

Have you prescribed Voxzogo?

Added By: wilson_admin

What advantages (if any) do you see infigratinib having over Voxzogo (vosoritide)?

Added By: wilson_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.